BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17614776)

  • 1. Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005.
    Grozinsky-Glasberg S; Benbassat CA; Tsvetov G; Feinmesser R; Peretz H; Shimon I; Lapidot M
    Thyroid; 2007 Jun; 17(6):549-56. PubMed ID: 17614776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
    Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
    G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic variables and calcitonin in medullary thyroid cancer.
    Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
    Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
    Barbet J; Campion L; Kraeber-Bodéré F; Chatal JF;
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6077-84. PubMed ID: 16091497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymph node metastases and elevated postoperative calcitonin: Predictors of poor survival in medullary thyroid carcinoma.
    Siironen P; Hagström J; Mäenpää HO; Louhimo J; Arola J; Haglund C
    Acta Oncol; 2016; 55(3):357-64. PubMed ID: 26339947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin.
    Karga H; Giagourta I; Papaioannou G; Doumouchtsis K; Polymeris A; Thanou S; Papamichael K; Zerva C
    Metabolism; 2011 May; 60(5):604-8. PubMed ID: 20667564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.
    Kebebew E; Ituarte PH; Siperstein AE; Duh QY; Clark OH
    Cancer; 2000 Mar; 88(5):1139-48. PubMed ID: 10699905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker-based risk stratification for previously untreated medullary thyroid cancer.
    Machens A; Dralle H
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2655-63. PubMed ID: 20339026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medullary thyroid cancer: surgical results and prognostic factors].
    Dequanter D; Lothaire P
    Rev Med Liege; 2010; 65(7-8):450-2. PubMed ID: 20857703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medullary thyroid carcinoma: long-term outcomes of surgical treatment.
    Abraham DT; Low TH; Messina M; Jackson N; Gill A; Chou AS; Delbridge L; Learoyd D; Robinson BG; Sidhu S; Sywak M
    Ann Surg Oncol; 2011 Jan; 18(1):219-25. PubMed ID: 20878247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Follow-up in Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels.
    Machens A; Lorenz K; Dralle H
    Ann Surg; 2009 Aug; 250(2):305-10. PubMed ID: 19638924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medullary thyroid carcinoma.
    Pacini F; Castagna MG; Cipri C; Schlumberger M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):475-85. PubMed ID: 20627492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of life expectancy in medullary thyroid cancer: age does not matter.
    de Groot JW; Plukker JT; Wolffenbuttel BH; Wiggers T; Sluiter WJ; Links TP
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):729-36. PubMed ID: 17121523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients.
    Pelizzo MR; Boschin IM; Bernante P; Toniato A; Piotto A; Pagetta C; Nibale O; Rampin L; Muzzio PC; Rubello D
    Eur J Surg Oncol; 2007 May; 33(4):493-7. PubMed ID: 17125960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medullary thyroid carcinoma with nodular goiter carries an excellent prognosis.
    Xu L; Wang WB; Zhao YP; Zhang TP; Liao Q; Chen G; Zhou L; Shu H
    J Surg Oncol; 2012 Aug; 106(2):169-73. PubMed ID: 22354558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination?
    Machens A; Hauptmann S; Dralle H
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2234-8. PubMed ID: 18364379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The variable pathologic presentations of medullary and micro-medullary thyroid carcinoma: an institutional experience.
    Samulski TD; Livolsi VA; Montone K; Baloch Z
    Pathol Res Pract; 2014 Mar; 210(3):182-5. PubMed ID: 24440099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioactive iodine treatment in medullary thyroid carcinoma.
    Faik Erdogan M; Gursoy A; Erdogan G; Kamel N
    Nucl Med Commun; 2006 Apr; 27(4):359-62. PubMed ID: 16531922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term prognosis of medullary thyroid carcinoma.
    Rendl G; Manzl M; Hitzl W; Sungler P; Pirich C
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):497-505. PubMed ID: 18331612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.